AstraZeneca, which received approval for Olaparib in 2018 ... been directed to withdraw the said indication and revise the package insert" the DCGI said in a letter, which was reviewed by Mint.

Olaparib is recommended, within its marketing authorisation, as an option for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults who ...

Patients with a form of breast cancer in England will be offered a new treatment after it was given the green light for NHS use. Olaparib will offer the chance of ‘longer, healthier lives’ for ...